DMIIR
Drugs Made In America Acquisition II Corp. RightKey Statistics
About Drugs Made In America Acquisition II Corp. Right
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company (SPAC) focused on identifying transformative opportunities within the pharmaceutical sector. Leveraging its management team's significant industry expertise and relationships, DMIIR aims to merge with and support innovative companies that enhance the domestic drug manufacturing landscape. By prioritizing the accessibility and affordability of U.S.-produced medicines, DMIIR is well-positioned to capitalize on the growing demands for sustainable and reliable healthcare solutions. This strategic approach not only seeks to drive substantial shareholder value but also fosters the growth of critical infrastructure within the American pharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $58.66M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting